Physician profile
Samuel Barrera
NPI 1861901811
$996.87
in general payments reported to CMS, 2019-2025
12 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $416 · 2023: $112 · 2024: $82.68 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $233.87 | 2021-2022 | |
| Abbvie INC. | $226.04 | 2022-2025 | |
| Novo Nordisk INC | $115.79 | 2021-2025 | Wegovy |
| Phadia US INC. | $104.76 | 2022-2023 | Immunocap |
| Amgen INC. | $97.16 | 2021 | |
| Lilly USA, LLC | $97.06 | 2022-2025 | Jardiance, Mounjaro |
| Exact Sciences Corporation | $23.87 | 2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $22.95 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $22.76 | 2025 | |
| Shield Therapeutics INC | $20.46 | 2024 | |
| Glaxosmithkline, LLC. | $18.39 | 2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.76 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.